Dr Reddy’s Laboratories, one of India’s top drugmakers with strong overseas play, is expected to report a healthy year-on-year growth in the domestic formulations business when it reports its third-quarter results on January 28.
Strong traction in chronic therapies and the addition of sales from Wockhardt’s portfolio would drive the growth, experts said. The Hyderabad-based firm’s main markets of the US and Canada are also expected to grow in the mid-teens.
The company is expected to report a consolidated net profit of Rs 780–780 crore for the quarter, up 22-25 percent from the year-ago period. On a sequential basis, the net profit is expected to decline 18-22 percent.
Brokerages expect the company to report a 10-15 percent year-on-year growth in consolidated revenue for the quarter at Rs 5,400–5,600 crore. On a sequential basis, the revenues may slip 3–6 percent.